A monkeypox vaccine from the Nordic country of Bavaria has received EU approval

OSLO, July 25 (Reuters) – Danish biotech company Bavarian Nordic ( BAVA.CO ) said on Monday the European Commission had given permission to market its vaccine Imvanek as protection against monkeypox, as recommended by the European Agency last week for medicines (EMA). ).

The approval comes just a day after the World Health Organization issued a high-level warning declaring the rapidly spreading monkeypox outbreak a global health emergency. In more detail

“The availability of an approved vaccine can significantly improve the preparedness of nations to fight new diseases, but only through investment and structured biological preparedness planning,” said Bavaria CEO Paul Chaplin.

Register now for FREE unlimited access to Reuters.com

The Bavarian vaccine, the only one approved for the prevention of monkeypox in the United States and Canada, has so far only been approved in the EU for the treatment of measles.

An employee of the vaccine company Bavarian Nordic shows an image of the vaccine virus on a display at the company’s laboratory in Martinsried near Munich, Germany, May 24, 2022. The company, based in Denmark, is the only one in the world to have approval for a measles vaccine called Jinneos in the US and Imvanek in Europe, which is also effective against monkeypox. REUTERS/Lukas Barth

But the company supplied the vaccine to several EU countries during the current monkeypox outbreak for what is known as “off-label” use.

The approval is valid in all member states of the European Union, as well as in Iceland, Liechtenstein and Norway, according to a statement from Bavaria Nordic.

The development of Imvanex was made possible by significant investments from the US government over the past two decades, the company added.

Bavaria’s share price has risen 122 percent in the past three months, boosted by strong demand for its monkeypox vaccine.

Register now for FREE unlimited access to Reuters.com

Reporting by Terje Solsvik; Editing by Himani Sarkar and Kim Coghill

Our Standards: Thomson Reuters Trust Principles.

Leave a Comment